PMC:7275137 / 47-184 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":67,"end":75},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma63836"}],"text":"ld be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inh"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":42,"end":50},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ld be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inh"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":67,"end":75},"obj":"http://purl.obolibrary.org/obo/GO_0005764"}],"text":"ld be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inh"}

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":53,"end":63},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ld be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inh"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":42,"end":50},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ld be considered as potential therapy for COVID-19 \n\nHighlights\n• Lysosome targeting agents can disrupt endolysosomal maturation and inh"}